Company: MBIO
Filing Date: 2025-02-21
Form Type: PRE 14C
Source: 0001104659-25-016146
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-21
Form: PRE 14C
Chunk 0
---
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14C INFORMATION

INFORMATION STATEMENT PURSUANT TO SECTION 14(C)
OF THE SECURITIES EXCHANGE ACT OF 1934</div>

Check the appropriate box:

| x | Preliminary Information Statement                                               |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) |
| ¨ | Definitive Information Statement                                                |

<div align='center'>Mustang Bio, Inc.

(Name of Registrant as Specified in its Charter)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required.                                                                                                                                                  |
| ¨ | Fee paid previously with preliminary materials.                                                                                                                   |
| ¨ | Fee computed on table in exhibit required by Item 25(b) of Schedule 14A (17 CFR 240.14a-101) per Item 1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11 |

<div align='center'>NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENTTHIS INFORMATION STATEMENT IS BEING PROVIDED TO THE
STOCKHOLDERS OF MUSTANG BIO, INC.

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

GENERAL INFORMATION</div>

This Notice and the accompanying
Information Statement (the “Information Statement”) are being furnished by Mustang Bio, Inc., a Delaware corporation (“Mustang,”
“we,” “our,” “us,” or the “Company”), to the holders of shares of our common stock, par
value $0.0001 per share, to inform you that, on February 19, 2025, the holders of a majority in voting power of issued and outstanding
shares of our common stock and issued and outstanding shares of our Class A Preferred Stock, par value $0.0001 (together, the “Majority
Holders”), approved, by written consent in lieu of a meeting (the “Written Consent”) the issuance of an aggregate of
up to 5,475,082 shares of our common stock underlying certain outstanding warrants issued by us pursuant to (A) that certain previously
disclosed Securities Purchase Agreement, dated as of February 5, 2025 (the “Purchase Agreement”), by and among the Company
and certain accredited investors signatory thereto